Premium
P4‐419: Pterocarpus erinaceus extract decreases β‐amyloid peptide production in an in‐vitro model
Author(s) -
Hage Salim,
KienlenCampard Pascal,
Octave JeanNoël,
QuetinLeclercq Joëlle
Publication year - 2011
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2011.09.115
Subject(s) - amyloid precursor protein , amyloid (mycology) , peptide , in vitro , chemistry , aqueous extract , erinaceus , pharmacology , p3 peptide , amyloid beta , traditional medicine , alzheimer's disease , biochemistry , biology , medicine , disease , gene , inorganic chemistry , hedgehog
ES1⁄4 0.28; Total ES1⁄4 0.30) also showedmild to moderate efficacy trends at Week 16 (Figure 1). No separation from placebo was observed on any other secondary endpoint at Week 16. The adverse event (AE) incidence was generally low, albeit slightly higher on GSK239512 (e.g. neuropsychiatric AEs involving insomnia, sleep, dreams and mood) than placebo, generally occurring early in titration and typically did not lead to study discontinuation. The maintenance phase AE incidence was similar between GSK239512 and placebo. The majority of AEs were mild to moderate in intensity. One subject in each treatment group experienced non-fatal serious adverse events on-therapy.Conclusions:GSK239512, at doses up to 80 micrograms, demonstrated mild to moderate effects on some measures of the computerised Cogstate battery. Other non-computerised measures showed no separation at Week 16. No obvious treatment moderators associated with effects were identified. In this study, GSK239512 appeared to be generally well tolerated with an AE profile consistent with its pharmacological profile.